Summary
Kathleen Dungan, MD, MPH, from The Ohio State University shares the current availability of GLP-1 agonists and SGLT-2 inhibitor medications and a look at the anticipated future of diabetes pharmacotherapies.
•
With just a few taps on your mobile device, easily explore and utilize valuable best practices resources.
Kathleen Dungan, MD, MPH, from The Ohio State University shares the current availability of GLP-1 agonists and SGLT-2 inhibitor medications and a look at the anticipated future of diabetes pharmacotherapies.